Keyphrases
Phase II Study
100%
Non-Hodgkin Lymphoma
100%
Relapsed or Refractory
100%
Hodgkin
100%
Darinaparsin
100%
Complete Response
75%
Overall Response Rate
50%
Stable Disease
50%
Peripheral T-cell Lymphoma
50%
Refractory Lymphoma
50%
Hematological Malignancies
25%
Anemia
25%
Consecutive Days
25%
Phase II Trial
25%
Lymphoma
25%
Nausea
25%
Confidence Interval
25%
Diarrhea
25%
Therapeutic Index
25%
Arsenic
25%
Antineoplastic Agents
25%
Lymphoma Patients
25%
Efficacy Index
25%
Partial Response
25%
Heavily Pretreated
25%
Heavily Pretreated Patients
25%
Organic Arsenic Compounds
25%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Darinaparsin
100%
Diseases
50%
Peripheral T-Cell Lymphoma
50%
Phase II Trials
25%
Nausea
25%
Anemia
25%
Hematologic Malignancy
25%
Anticarcinogen
25%
Diarrhea
25%
Chemotherapeutic Agent
25%
Arsenic Derivative
25%
Therapeutic Window
25%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Darinaparsin
100%
Peripheral T Cell Lymphoma
50%
Disease
50%
Arsenic Compound
25%
Phase II Trials
25%
Hematologic Malignancy
25%
Anticarcinogen
25%
Diarrhea
25%
Nausea
25%
Therapeutic Window
25%
Anemia
25%